Chimeric Peptide Vaccine Design for Broad Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development methods are inadequate for viruses like HCV, CMV, and Influenza, which exhibit high mutation frequencies and persistence in the body, leading to chronic infections and evading immune surveillance, necessitating new approaches to stimulate effective adaptive immune responses.
Innovation Solution
Design of cell-penetrating peptides that can be taken up by antigen-presenting cells, processed, and presented to T-lymphocytes to stimulate both CD4+ and CD8+ T-lymphocyte responses, utilizing specific amino acid sequences that enhance uptake and immune response induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional inactivated virus vaccines are used, then antibody responses are induced, but cell-mediated immunity is not effectively stimulated
Solution Approach 1:
The patent combines epitope peptides from multiple viral sources (HCV, CMV, Influenza) into a single chimeric peptide construct that can simultaneously stimulate both humoral and cell-mediated immune responses through a single vaccination approach
Solution Approach 2:
The cell-penetrating peptide sequence acts as an intermediary that facilitates the delivery of epitope peptides into antigen-presenting cells, enabling effective presentation to T-lymphocytes and stimulation of cell-mediated immunity
2Reliability
If live attenuated vaccines are used, then both cell-mediated immunity and antibody response are induced, but the virus must be replication competent which raises safety concerns
Solution Approach 1:
The patent extracts only the essential immunogenic components (epitope peptides) from the complete virus structure, removing the replication-competent viral genome while retaining the ability to stimulate both humoral and cell-mediated immune responses
Solution Approach 2:
The vaccine construct is segmented into distinct functional modules: cell-penetrating peptide sequences for delivery, epitope peptides from multiple viruses for broad immunity, and linkers for structural integrity, allowing independent optimization of each component
3Productivity
If peptides are designed to penetrate cell membranes, then uptake by antigen-presenting cells is enhanced, but peptide structure complexity increases
Solution Approach 1:
The patent utilizes specific amino acid sequence parameters (basic residues like arginine and lysine at defined positions) to confer cell-penetrating properties on the peptide construct, optimizing the balance between uptake efficiency and structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively penetrate cells and induce a cytotoxic T-lymphocyte and humoral immune response, providing a novel mechanism for vaccine development against viruses with high mutation rates and persistence.
Implementation Method 1
Several peptides have been demonstrated to translocate across the plasma membrane of eukaryotic cells by a seemingly energy-independent pathway. These peptides are defined as cell-penetrating peptides (CPPs).
Data Source
AI summary
The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.